Zyversa Therapeutics Inc
NASDAQ:ZVSA
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
Z
|
Zyversa Therapeutics Inc
NASDAQ:ZVSA
|
1.4m USD |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
383.2B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
201.5B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
181.6B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
120.9B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
82.6B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
87.9B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
43.9B EUR |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
Other Profitability Ratios
Zyversa Therapeutics Inc
Glance View
ZyVersa Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. The company is headquartered in Weston, Florida. The company went IPO on 2021-12-21. The firm is focused on leveraging advanced technologies to develop drugs for patients with renal or inflammatory diseases. The Company’s development pipeline includes renal drug candidate, namely VAR 200, (2-hydroxypropyl-beta-cyclodextrin or 2HPβCD), a cholesterol efflux mediator for treatment of rare kidney disease, focal segmental glomerulosclerosis. Its VAR 200 has potential to treat other glomerular diseases, including alport syndrome and diabetic kidney disease. The firm's development pipeline also includes anti-inflammatory drug candidate, namely IC 100, an inflammasome ASC inhibitor being developed to treat a multitude of inflammatory diseases. Its phase 2a renal product candidate, VAR 200, which mediates removal of excess intracellular lipids that contribute to kidney damage leading to end-stage renal disease.
